 |
|
|
|
|
|
| |
2012
-
14May
May, Monday 14, 2012¬ 09:43 EDT
Apricus Biosciences to Present at the 11th Annual JMP Securities Research Conference
-
11May
May, Friday 11, 2012¬ 09:56 EDT
Health Canada Grants Apricus Biosciences Pre-NDS Meeting for MycoVa™ for the Treatment of Onychomycosis
-
08May
May, Tuesday 08, 2012¬ 09:50 EDT
Apricus Biosciences Announces First Quarter 2012 Financial Results Conference Call and Provides Corporate Update
-
07May
May, Monday 07, 2012¬ 10:11 EDT
Health Canada Grants Apricus Biosciences Pre-NDS Meeting for Femprox for Female Sexual Arousal Disorder
-
04May
May, Friday 04, 2012¬ 10:06 EDT
Apricus Biosciences Announces Poster Presentation of Femprox® Phase III Clinical Data at American Urological Association Annual Meeting
-
27apr
April, Friday 27, 2012¬ 10:37 EDT
Apricus Biosciences Shareholder Notice: Vice President Edward Cox Interviewed on OneMedPlace
-
26apr
April, Thursday 26, 2012¬ 12:02 EDT
Apricus Biosciences Receives Notice of Issuance for First Prevonco™ Patent in the United States
-
22Mar
March, Thursday 22, 2012¬ 07:01 EDT
Apricus Biosciences Announces Allowance of a NexACT® Technology-Based Patent in Europe for the Manufacture of DDAIP
-
14Mar
March, Wednesday 14, 2012¬ 10:06 EDT
Apricus Biosciences, San Diego Hospice And The Institute For Palliative Medicine Announce A Broad Clinical Research Program Using Nexact® Technology
-
09Mar
March,Friday 09, 2012¬ 08:01 EDT
Apricus Biosciences' CEO to Present at the 24th Annual ROTH OC Growth Stock Conference
-
08Mar
March, Thursday 08, 2012¬ 14:22 EDT
Apricus Biosciences Announces 2011 Year End Financial Results Conference Call
-
08Mar
March, Thursday 08, 2012¬ 10:04 EDT
Apricus Biosciences, Inc [APRI] to Ring The NASDAQ Stock Market Closing Bell
-
06Mar
March, Tuesday 06, 2012¬ 10:01 EDT
APRICUS BIOSCIENCES CEO IS INTERVIEWED ON CDTV.NET
-
16Feb
February, Thursday 16, 2012¬ 10:08 EDT
Apricus Biosciences Announces Shareholder Update With New Focus as a Commercially-Driven Specialty Pharmaceutical Company
-
15Feb
February, Wednesday 15, 2012¬ 12:37 EDT
Apricus Bioscience's Wholly-Owned Subsidiary NexMed (USA) Signs Exclusive German Collaboration for Vitaros® for Erectile Dysfunction
-
09Feb
February, Thursday 09, 2012¬ 09:30 EDT
Apricus Biosciences Prices $20.0 Million Public Offering Of Common Stock And Warrants
-
08Feb
February, Wednesday 08, 2012¬ 17:22 EDT
Apricus Biosciences Announces Proposed Public Offering Of Common Stock And Warrants
-
03Feb
February, Friday 03, 2012¬ 11:27 EDT
Apricus Biosciences Announces Acquisition Of Nitromist™ Rights Outside North America
-
27Jan
January, Friday 27, 2012¬ 08:02 EDT
Apricus Biosciences Expands Commercial Oncology Offerings Through Agreement With Pediatrx for U.S. Co-Promotion of GRANISOL® (Granisetron) Oral Solution ...
-
19Jan
January, Tursday 19, 2012¬ 11:02 EDT
Apricus Biosciences Retains Argot Partners As Investor Relations Firm
-
17Jan
January, Tuesday 17, 2012¬ 10:08 EDT
Apricus Biosciences Announces Allowance of Israeli Patent, Expanding Its Patent Portfolio for the Topical Treatment of Premature Ejaculation
-
10Jan
January, Tuesday 10, 2012¬ 10:56 EDT
Apricus Biosciences and Elis Pharma Sign License Agreement for MycoVa™ in the Middle East and the Gulf
-
09Jan
January, Monday 09, 2012¬ 16:16 EDT
Apricus Biosciences To Webcast Today’S Presentation At Biotech Showcase™ 2012 In San Francisco
-
09Jan
January, Monday 09, 2012¬ 12:34 EDT
Apricus Biosciences and Abbott Sign Exclusive Agreement to Market Vitaros® (Alprostadil) in Canada
-
04Jan
January, Wednesday 04, 2012¬ 09:55 EDT
Apricus Biosciences CEO, Dr. Bassam Damaj, to Present at Biotech Showcase™ 2012 in San Francisco
-
03Jan
January, Tuesday 03, 2012¬ 10:05 EDT
Apricus Biosciences and Stellar Pharmaceuticals Announce Exclusive License Agreement in Canada for the Commercialization of MycoVa™ for Onychomycosis
2011
-
29Dec
December, Thursday 29, 2011¬ 12:35 EDT
Apricus Biosciences Completes Acquisition of Topotarget USA, Inc.
-
16Dec
December, Friday 16, 2011¬ 08:06 EDT
Apricus Biosciences Launches Commercialization Arm With Definitive Agreement to Acquire Topotarget USA
-
15Dec
December, Thursday 15, 2011¬ 10:05 EDT
Apricus Biosciences Announces Oral Presentation of Efficacy and Clinical Safety Data for Vitaros® and Femprox® at the African Society for Sexual Medicine Conference
-
12Dec
December, Monday 12, 2011¬ 11:58 EDT
Apricus Biosciences' Vitaros® Podium Presentation Named Best Clinical Presentation 2011 (Male Sexual Disorder) by the Scientific Committee of the Congress ...
-
08Dec
December, Thursday 08, 2011¬ 10:06 EDT
Apricus Biosciences Announces Allowance of Additional NexACT® Patent in Japan
-
30Nov
November, Wednesday 30, 2011¬ 09:48 EDT
Apricus Biosciences Announces Podium Presentation of Efficacy and Clinical Safety Data for Vitaros® at the European Sexual Society Medicine Conference
-
21Nov
November, Monday 21, 2011¬ 09:56 EDT
Apricus Biosciences Announces Appointment of Dr. Kleanthis G. Xanthopoulos to Its Board of Directors
-
15Nov
November, Tuesday 15, 2011¬ 09:36 EDT
Apricus Biosciences Announces That Its NexACT® Partner Exodos Life Sciences Has Completed Its pre-IND Meeting With the FDA
-
14Nov
November, Monday 14, 2011¬ 09:52 EDT
Femprox® Phase III Clinical Data From Apricus Biosciences Chosen for a Presentation at the European Society for Sexual Medicine
-
11Nov
November, Friday 11, 2011¬ 13:21 EDT
Apricus Biosciences Announces Third Quarter 2011 Financial Results Conference Call
-
19Oct
October, Wednesday 19, 2011¬ 10:36 EDT
Apricus Biosciences Announces Issuance of Korean Patent, Expanding Its Patent Portfolio for Its Topical Cream to Treat Premature Ejaculation
-
13Oct
October, Thursday 13, 2011¬ 11:21 EDT
Apricus Biosciences Announces New Data Published in the International Journal of Pharmaceutics Confirming Efficiency of NexACT® Drug Delivery Technology
-
10Oct
October, Monday 10, 2011¬ 10:36 EDT
Apricus Biosciences Announces Presentation of Efficacy and Clinical Safety Data for Vitaros® at Upcoming Industry Conference
-
06Oct
October, Thursday 06, 2011¬ 10:57 EDT
Apricus Biosciences to Present Poster of Femprox® Phase III Clinical Data at Upcoming Industry Conference
-
04Oct
October, Tuesday 04, 2011¬ 10:06 EDT
Apricus Biosciences to Present NexACT® Technology Overview at PODD Drug Delivery Conference
-
03Oct
October, Monday 03, 2011¬ 11:08 EDT
Apricus Biosciences Announces Korean Patent Approval for MycoVa™ for Nail Fungus
-
09Sep
September, Friday 09 2011¬ 14:28 EDT
Apricus Biosciences to Provide Overview of Rx and Consumer Healthcare Divisions at the 11th Annual Biotech in Europe Investor Forum
-
02Sep
September, Friday 02 2011¬ 10:38 EDT
Apricus Biosciences Corrects the Terminology Relating to Its OTC Products
-
15Aug
August, Thursday 15 2011¬ 10:08 EDT
Apricus Biosciences Announces Expansion of Its NexACT® Patent Portfolio
-
11Aug
August, Thursday 11 2011¬ 16:35 EDT
Apricus Biosciences Announces Second Quarter 2011 Financial Results Conference Call
-
11Aug
August, Thursday 11 2011¬ 11:39 EDT
Apricus Biosciences CEO Interviewed on CEOLIVE.TV
-
08Aug
August, Monday 08 2011¬ 10:08 EDT
Apricus Biosciences To File For Market Authorization To Sell Vitaros® For Erectile Dysfunction In Latin America
-
04Aug
August, Thursday 04 2011¬ 13:27 EDT
Apricus Biosciences Provides Corporate Mid-Year Update
-
19Jul
July, Tuesday 19 2011¬ 09:59 EDT
Apricus Biosciences Files Marketing Application for Vitaros® as a Treatment for Erectile Dysfunction in Switzerland
-
06Jul
July, Wednesday 06 2011¬ 09:05 EDT
Apricus Biosciences Sells Bio-Quant CRO Subsidiary to BioTox Sciences
-
28Jun
June, Tuesday 28 2011¬ 10:52 EDT
Apricus
Biosciences' Marketing Application for Vitaros®, for the
Treatment of Erectile Dysfunction, is Accepted for Review in
Europe
-
27Jun
June, Monday 27 2011¬ 10:19 EDT
Apricus Biosciences Reports Reanalysis of Its U.S. Phase III Trials for MycoVa Showing Drug is Effective in Mycological Cure Resulting in Eradication of Nail Fungus
-
24Jun
June, Friday 24 2011¬ 10:40 EDT
Apricus Bio CEO Bassam Damaj to Present at the 2011 Biotechnology Industry Organization (BIO) International Convention
-
17Jun
June, Friday 17 2011¬ 14:28 EDT
Apricus Biosciences' CEO Sees Higher Revenue if Pfizer Viagra® Litigation is Successful
14Jun
June, Tuesday 14 2011¬ 09:49 EDT
Apricus Biosciences Added to Russell Microcap Index
-
03Jun
June, Friday 03 2011¬ 10:23 EDT
Apricus Bio CEO to Present Commercialization Plans for Vitaros® at Jefferies 2011 Global Healthcare Conference
-
02Jun
June, Thursday 02 2011¬ 12:06 EDT
Apricus Biosciences Appoints Steve Martin as Senior Vice President and Chief Financial Officer
-
01Jun
June, Wednesday 01 2011¬ 15:10 EDT
Apricus Biosciences Produces Videos Describing the Mechanism by Which Its NexACT® Technology Successfully Delivers Drugs Through the Skin
-
31May
May, Tuesday 31 2011¬ 9:56 EDT
Apricus Biosciences Announces Issuance of Key Patent for RayVa for Raynaud's Phenomenon in Israel
-
26May
May, Thursday 26 2011¬ 13:40 EDT
Apricus Biosciences' CEO to Present at Jefferies 2011 Global Healthcare Conference
-
23May
May, Monday 23 2011¬ 13:43 EDT
Apricus Biosciences to Present at the Euro-Biotech Partnering Forum 2011 to Further Its Partnership Efforts
-
19May
May, Thursday 19 2011¬ 9:50 EDT
Apricus Biosciences Will Request Approval of Vitaros® as a Treatment for Erectile Dysfunction in Switzerland, Based on Guidance From Swiss Regulatory Authorities
-
18May
May, Wednesday 18 2011¬ 11:05 EDT
Apricus Biosciences CEO is Interviewed on CDTV.net
-
10May
May, Tuesday 10 2011¬ 13:55 EDT
Apricus Biosciences Appoints Randy Berholtz as Executive Vice President, General Counsel and Secretary
-
10May
May, Tuesday 10 2011¬ 9:28 EDT
Apricus Biosciences Announces First Quarter 2011 Financial Results Conference Call
-
03May
May, Tuesday 03 2011¬ 10:22 EDT
Apricus Biosciences' Corporate Development Executive Interviewed on Steve Crowley's American Scene
-
28Apr
April, Thursday 28 2011 ¬ 10:11 EDT
Apricus Biosciences
Requests Approval of Vitaros® as a Treatment for
Erectile Dysfunction in Europe
-
27Apr
April, Wednesday 27 2011 ¬ 13:01 EDT
Apricus Biosciences
to Present at the FSX Investor Conference in San Francisco on
April 28, 2011
-
19Apr
April, Tuesday 19 2011 ¬ 10:35 EDT
Apricus Biosciences
Building Strong Pipeline and Solid Financials, CEO, Dr. Bassam
Damaj, Tells CEO/CFO Magazine
-
13Apr
April, Wednesday 13 2011 ¬ 15:40 EDT
Apricus Biosciences
Files for Orphan Drug Designation for RayVa™
-
05Apr
April, Tuesday 05 2011 ¬ 12:22 EDT
Apricus Biosciences'
CEO Interviewed by WallStreetCorner.com
-
31Mar
March, Thursday 31 2011 ¬ 10:46 EDT
Apricus Biosciences
Expands Patent Coverage in Mexico for Its Erectile Dysfunction
Drug, Vitaros®
-
24Mar
March, Thursday 24 2011 ¬ 9:59 EDT
Apricus Biosciences
Adopts Shareholder Rights Plan
-
22Mar
March, Tuesday 22 2011 ¬ 9:55 EDT
Apricus Biosciences
Announces Poster Presentations on Progress of PrevOnco™
in Combination With NexACT® Technology at the American
Association for Cancer Research 2011 Annual Meeting
-
15Mar
March, Tuesday 15 2011 ¬ 10:01 EDT
Apricus Biosciences
Announces Formation of Clinical Advisory Board as Part of Its
Plans to Further the Clinical Development of Femprox®
-
10Mar
March, Thursday 10 2011 ¬ 9:58 EDT
Apricus Biosciences
to Present at the Bio-Europe Spring 2011 Conference
-
09Mar
March, Wednesday 09 2011 ¬ 9:31 EDT
Apricus Biosciences
Announces 2010 Year End Financial Results Conference Call
-
08Mar
March, Tuesday 08 2011 ¬ 9:59 EDT
Apricus Biosciences
Announces Removal of Auditor's "Going Concern" Opinion From
Its 2010 Form 10-K and Increased Cash Reserves
-
01Mar
March, Tuesday 01 2011 ¬ 9:16 EDT
Apricus Biosciences
Announces Expanded European Patent Coverage for MycoVa
for Nail Fungus
-
17Feb
February, Thursday 17 2011 ¬ 9:17
EDT
Apricus Biosciences
and FDA Initiate PrevOnco SPA Phase III Clinical Protocol
Discussion
-
14Feb
February, Monday 14 2011 ¬ 10:20 EDT
Apricus Biosciences
and Neopharm Group Sign Licensing Agreement for Vitaros®
in Israel for up to $4.35 Million, Plus Royalties
-
10Feb
February, Thursday 10 2011 ¬ 10:14
EDT
Apricus Biosciences
to Present Review of Commercialization Plans for Vitaros®
and Development of Product Pipeline at BioPartnering North America
Conference(TM)
-
-
28jan
January, Friday 28 2011 ¬ 11:03 EDT
Apricus Biosciences
Presents Data on Oral Use of Nexact(R) Technology at the Controlled
Release Society Conference
-
26jan
January, Wednesday 26 2011 ¬ 12:03
EDT
Apricus Biosciences'
Chief Executive Officer is Interviewed on CDTV.net
-
19jan
January, Wednesday 19 2011 ¬ 12:03
EDT
Apricus Biosciences
Reports Additional Analysis Showing That MycoVa™ is as
Effective for the Treatment of Nail Fungus as the Current European
Standard of Care for Topical Therapy, Loceryl(R)
-
14jan
January, Friday 14 2011 ¬ 12:03 EDT
Apricus Bio
Announces Expansion Of Patent Portfolio for Topical Cream to
Treat Premature Ejaculation with Issuance Of Japanese Patent
-
12jan
January, Wednesday 12 2011 ¬ 13:51
EDT
Management of
Apricus Bio Highlights Corporate Development, Drug Registration
and Out-Licensing Progress at Two Biotech Conferences
-
04jan
January, Tuesday 04 2011 ¬ 10:13 EDT
Apricus Biosciences
and Elis Pharma Sign License Agreement for Vitaros®
in the Gulf and Part of the Middle East; Apricus Bio to Receive
up to $2.1 Million, Plus Royalties
2010
-
22dec
December, Wednesday 22 2010 ¬ 11:12 EDT
Apricus Biosciences and Bracco Sign Licensing Agreement for Vitaros® in Italy; Apricus Bio to Receive Up to EUR 5.5 Million, Plus Royalties
-
13dec
December, Monday 13 2010 ¬ 14:00 EDT
Apricus Biosciences Announces Upcoming Presentations at the 4th Annual OneMedForum San Francisco and the Biotech Showcase 2011
-
06dec
December, Monday 06 2010 ¬ 14:54 EDT
Apricus Biosciences Launches Educational Video Series Focused On Its Newly Approved Erectile Dysfunction Drug, Vitaros®
-
01dec
December, Wednesday 01 2010 ¬ 15:59 EDT
Apricus Biosciences Appoints Manufacturer for Vitaros® , Its Newly Approved Drug to Treat Erectile Dysfunction in Canada
-
29nov
November, Monday 29 2010 ¬ 15:12 EDT
Apricus Biosciences Announces New NexACT® Transbuccal Delivery Data Published in the International Journal of Pharmaceutics
-
22nov
November, Monday 22 2010 ¬ 15:13 EDT
Apricus Biosciences Files Phase 3 Registration Protocol for PrevOnco™ for Special Protocol Assessment Consideration by the FDA
-
19nov
November, Friday 19 2010 ¬ 15:03 EDT
Apricus Bio Announces Pre-Clinical Data Showing Significant Improvement in Solubility and Absorption of NexACT® -Based Small Molecule Drugs Selected from the Biopharmaceutics Classification System
-
17nov
November, Wednesday 17 2010 ¬ 15:00 EDT
Apricus Biosciences' CEO Bassam Damaj, Ph.D., Interviewed by the Financial Network CDTV.net
-
15nov
November, Monday 15 2010 ¬ 17:21 EDT
Apricus Biosciences Receives Canadian Approval for Vitaros® as First Line Therapy for Erectile Dysfunction
-
10nov
November, Wednesday 10 2010 ¬ 15:39 EDT
Apricus Biosciences Announces 2010 Third Quarter Financial Results Conference Call
-
09nov
November, Tuesday 09 2010 ¬ 17:40 EDT
Apricus Bio's VP of Investor Relations, Edward Cox, Interviewed by Steve Crowley's American Scene
-
05nov
November, Friday 05 2010 ¬ 16:35 EDT
Apricus Bio
Apricus Bio Awarded Three Qualifying Therapeutic Discovery Project Grants
-
25oct
October, Monday 25 2010 ¬ 16:40 EDT
Apricus Bio
Announces Formation of Clinical Advisory Board
-
21oct
October, Thursday 21 2010 ¬ 13:01 EDT
Apricus Biosciences to Present at the FSX Investor Conference in Phoenix, AZ on October 29, 2010
-
18oct
October, Monday 18 2010 ¬ 16:30 EDT
Apricus Bio Announces First Patent Grant for Femprox® In Japan
-
14oct
October, Thursday 14 2010 ¬ 14:00 EDT
Apricus Bio
Announces IND Filing for Nupen™, Its Proprietary Topical
Nupen™ Formulation Containing NexACT®
-
13oct
October, Wednesday 13 2010 ¬ 14:02 EDT
Apricus Bio Provides Update on Development Activities
-
11oct
October, Monday 11 2010 ¬ 13:00 EDT
Apricus Biosciences To Present At The Precisionir Informed Investors Forum Biotech, Healthcare And Pharma
Virtual Conference On October 13
-
08oct
October, Tuesday 08 2010 ¬ 13:00 EDT
Apricus Bio Highlighted in Investment Newsletter
-
05oct
October, Tuesday 05 2010 ¬ 12:00 EDT
Apricus Bio Closes Securities Offering, Raising over $9.3 Million
-
29sep
September, Wednesday 29 2010 ¬ 12:30 EDT
Apricus Bio Announces Pricing of Securities Offering
-
21sep
September, Tuesday 21 2010 ¬ 19:11 EDT
Apricus Bio Receives FDA Guidance on Phase 3 Study Design for RayVa™ Treatment for Raynaud's Syndrome, Secondary to Scleroderma
-
20sep
September, Monday 20 2010 ¬ 15:00 EDT
Apricus Bio Announces Confirmatory Results Qualifying NexACT® as an Anti-Microbial Preservative
-
14sep
September, Tuesday 14 2010 ¬ 13:50 EDT
Apricus Biosciences Announces Pre-Clinical Results Showing the Ability of the NexACT® Technology to Enable Rectal Delivery of Biologics
-
10sep
September, Friday 10 2010 ¬ 20:31 EDT
NexMed, Inc. Announces Results of Special Meeting of Stockholders, Including Name Change to Apricus Biosciences
-
25aug
August, Wednesday 25 2010 ¬ 15:00 EDT
NexMed To Present at the Rodman & Renshaw 12th Annual Healthcare Conference
-
23aug
August, Monday 23 2010 ¬ 13:00 EDT
NexMed Receives Additional Patent Coverage for Israel
-
26jul
July, Monday 26 2010 ¬ 16:36 EDT
Mohamed Hachicha, Ph.D. Joins NexMed, Inc. as Vice President-Research and Development for NexMed, USA
-
07jul
July, Wednesday 07 2010 ¬ 12:30 EDT
NexMed Regains Compliance with NASDAQ Listing Requirements
-
28jun
June, Monday 28 2010 ¬ 16:09 EDT
NexMed to Present PrevOnco™ Data at ILCA Annual Conference
-
24jun
June, Thursday 24 2010 ¬ 17:20 EDT
NexMed Announces First Patent Allowance for Vitaros® in Japan
-
23jun
June, Wednesday 23 2010 ¬ 17:54 EDT
NexMed Receives Screening Acceptance Letter from Health Canada for Vitaros®
-
22jun
June, Tuesday 22 2010 ¬ 13:15 EDT
NexMed Announces Appointment of Deirdre Y. Gillespie, M.D. to the Board of Directors
-
15jun
June, Tuesday 15 2010 ¬ 13:20 EDT
NexMed Announces Pre-Clinical Results Showing That Its Proprietary Calcipotriene Betamethasone Psoriasis Formulation is Bioequivalent to Talconex®
-
10jun
June, Thursday 10 2010 ¬ 9:07 EDT
NexMed Provides Update on Canadian Filing for Vitaros®
-
25may
May, Tuesday 25 2010 ¬ 21:00 EDT
NexMed Announces Expansion of Senior Business Development Team
-
17may
May, Monday 17 2010 ¬ 21:11 EDT
NexMed to Discuss P2/3 Protocol for NexACT® -Based Alprostadil Treatment for Raynaud's Syndrome with the FDA
-
12may
May, Wednesday 12 2010 ¬ 15:19 EDT
Nexmed Announces Pre-Clinical Study Showing
Vitaros® Significantly Promotes Wound Healing
-
10may
May, Monday 10 2010 ¬ 21:19 EDT
NexMed Announces Encouraging Pre-Clinical Results Showing the Ability of the NexACT® Technology to Enhance the Bioavailability of rituximab When Administered Subcutaneously
-
06may
May, Thursday 6 2010 ¬ 20:45 EDT
NexMed Expands Scientific Advisory Board with Appointment of Key Industry Leaders
-
05may
May, Wednesday 5 2010 ¬ 20:36 EDT
NexMed Announces Patent Allowance for NexACT® in Canada
-
28Apr
April, Wednesday 28 2010 ¬ 22:47 EDT
Pre-Clinical Results Show NexACT® Technology Significantly Improves Subcutaneous Delivery and Anti-Metastatic Activity of Angstrom's A6 Cancer Compound
-
27Apr
April, Tuesday 27 2010 ¬ 20:40 EDT
NexMed Appoints Dr. Stephen B. Howell, World Renowned Key Opinion Leader in Oncology as Chairman of Its Scientific Advisory Board
-
26Apr
April, Monday 26 2010 ¬ 14:11:23 EDT
NexMed Receives FDA Clearance for PrevOnco™ Phase 2 Study as First-Line Therapy for HCC
-
22Apr
April, Friday 22 2010 ¬ 00:50 EDT
NexMed Files CMC Response with Health Canada for Vitaros®
-
13Apr
April, Tuesday 13 2010 ¬
15:00 EDT
NexMed and Ångstrom Pharmaceuticals to Present Data on Å6 Drug at AACR
-
09Apr
April, Friday 09 2010 ¬
13:00 EDT
NexMed Announces Expansion of Its Bio-Quant Subsidiary Facilities
-
05Apr
April, Monday 05 2010 ¬
13:15 EDT
NexMed Announces the Expansion of Its Senior Management Team
-
29Mar
March, Monday 29 2010 ¬
11:18 EDT
Nexmed Files Investigational New Drug Application with Fda for Cancer Drug Candidate
-
25Mar
March, Thursday 25 2010 ¬
14:00 EDT
NexMed, Inc. to Co-Sponsor Biotalk of Dr. Diego Miralles of Johnson & Johnson at the San Diego Biotechnology Discussion Group
-
23Mar
March, Tuesday 23 2010 ¬
17:21 EDT
NexMed, Inc. Enters into Distribution Agreement for Japan
-
17Mar
March, Wednesday 17 2010 ¬
14:00 EDT
NexMed Announces the Ability of Its NexACT® Technology to Deliver Insulin and Taxol Subcutaneously in a Depot-Like Fashion
-
17Mar
March, Wednesday 17 2010 ¬
12:30 EDT
NexMed Bolsters Its Cash Reserve with $1.4 Million Infusion from Successful Mortgage Refinancing on Its New Jersey Facility
-
09Mar
March, Tuesday 09 2010 ¬
11:06:15
Nexmed To Present At The Roth 22Nd Annual Oc Growth Stock Conference
-
08Feb
February, Monday 08 2010 ¬
14:54:29
NexMed Receives over $2.7 Million Cash Infusion
-
01Feb
February, Monday 01 2010 ¬
14:54:29
NexMed Granted Request for Continued Listing on NASDAQ
-
19Jan
January, Tuesday 19 2010 ¬
14:54:29
Nexmed Updates on Canadian Aproval Process for Vitaros®
-
12Jan
January, Tuesday 12 2010 ¬
14:54:29
NexMed Announces the Ability of the NexACT® Technology to Deliver Drugs Orally and with Enhanced Bioavailability
-
08Jan
January, Friday 08 2010 ¬
10:48:29
NexMed Provides Corporate Update
|
|
 |